DisEMBARK? FDA Questions Accelerated Approval Impact On Sarepta’s Fully Enrolled Clinical Trial

 
• By Sue Sutter

Advisory committee will consider how approval of SRP-9001 now might affect completion of the 52-week endpoint in EMBARK, a fully enrolled trial with two-thirds of the subjects coming from the US. Sarepta says all study subjects will have guaranteed access to the DMD gene therapy by end of September, making the risk of dropout ‘extremely low.’

Gangplank
US FDA questions whether US study subjects will leave the EMBARK trial if SRP-9001 receives accelerated approval. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers